

ICR Presentation

January, 2020

OUR MISSION:

To deliver a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and services.



FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events, including statements regarding the proposed acquisition of VIP Petcare by PetIQ, the expected closing date of the acquisition and the potential benefits and synergies of the acquisition. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could" and similar expressions. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forwardlooking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, our ability to successfully grow our business through acquisitions; our dependency on a limited number of customers; our ability to implement our growth strategy effectively; our ability to sustain profitability; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; our ability to introduce new products and improve existing products; our failure to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; and the risks set forth under the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2018 and other filings from time to time with the Securities and Exchange Commission.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.

This presentation includes Adjusted EBITDA, a non-GAAP financial measure. This non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please refer to the Appendix of this presentation for a reconciliation of adjusted EBITDA to net income, the most directly comparable financial measure prepared in accordance with U.S. GAAP.

The Company does not provide outlook for net income, and similarly cannot provide a reconciliation between its 2019 adjusted EBITDA outlook and net income without unreasonable effort due to the unavailability of reliable estimates for certain reconciling items. These items are not within the Company's control and may vary greatly between periods and could significantly impact future financial results.





WHAT WE DO & WHY


PET IQ.



VETERINARY SERVICES • PHARMACEUTICALS • PET PRODUCTS

REDEFINING VETERINARY SOLUTIONS

RETAIL MARKETPLACE



VETERINARY SERVICES • PHARMACEUTICALS • PET PRODUCTS



PETIC: Delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and services.







COMPANY OVERVIEW

WE TAKE CARE OF PETS & HELP PET PARENTS SAVE MONEY

VETERINARY SERVICES \$ 28.5 Billion in 2019 *

PET IQ. Veterinary Clinics

- Over 1,200,000 Pets served in 2019
- Retail Partners
- Mobile Community Clinics
- Wellness Centers
- Opened 80 Wellness Centers in 2019
- Plan to Open 1,000 Wellness
 Centers by 2023

VETERINARY PET MEDICATIONS \$ 9 Billion in 2019 *

PET IQ Distributed Product

- 500+ Distributed Medications
- Prescription and OTC
- Leading Animal Health Partner to Retailers
- Leading Partner to Animal Health Manufacturing
- 24 Hour Delivery to
 Any Pharmacy

NexGard

PET IQ. Manufactured Product

- 780,000+ Square Feet of Our Own Facilities
- Over 1,200 Items Manufactured
 Flea & Tick

PETARMOR

- Health & Wellness
- Prescription Drug
- Treats
- EPA/FDA Licensed
- SQF Certified

FRONTLINE




WE PARTNER WITH TOP RETAILERS TO PROVIDE PRODUCTS AND SERVICES AT AFFORDABLE COSTS AND GREATER CONVENIENCE TO PET PARENTS



VETERINARY SERVICES • PHARMACEUTICALS • PET PRODUCTS

GROWTH TRAJECTORY REMAINS INTACT




Notes: 1 - Non-GAAP financial measure. See the Appendix of this presentation for a reconciliation of the most comparable GAAP measure.

PET IQ.



SERVICES

NATIONWIDE INFRASTRUCTURE



Where We Operate – CURRENT FOOTPRINT

OPERATING VETERINARY CLINICS NEAR 90% OF THE U.S. POPULATION

POSITION IN THE MARKET

Service Provider	Footprint Coverage (States)	Multiple Partnerships	Top 20 US Pet Retailer	Non-Pet Retailers	Mobile Clinics	Wellness Centers
PETIQ	41	✓	12	✓	✓	✓
BANFIELD PET HOSPITALS	44	X	1	X	X	\checkmark
NATIONAL VETERINARY ASSOCIATES (NVA)	43	x	0	x	x	\checkmark
VCA ANIMAL HOSPITALS	43	X	0	X	X	✓
VETCO (PETCO)	32	X	1	x	\checkmark	\checkmark
SHOTVET	5	\checkmark	2	\checkmark	\checkmark	X
GOOD NEIGHBOR VET	3	\checkmark	2	\checkmark	\checkmark	X
PET PREVENTIVE CARE	3	\checkmark	0	X	✓	\checkmark
VAXSMART	3	\checkmark	1	\checkmark	✓	X
THRIVE	3	X	1	X	x	\checkmark
AFFORDABLE PET VACCINES	2	\checkmark	0	\checkmark	\checkmark	\checkmark
EZ VET	2	x	1	X	x	\checkmark
PETSTOP	2	\checkmark	0	\checkmark	\checkmark	X
ESSENTIALS PETCARE	2	x	1	\checkmark	x	\checkmark
VACCINATION STATION	1	\checkmark	0	\checkmark	\checkmark	X

OUR VETERINARY SERVICE FOOTPRINT

COMMUNITY CLINICS: OUR MOBILE MODEL

WELLNESS CENTERS: OUR FIXED MODEL



- Legacy Business Had Double-Digit Growth in 2019
- Over 70K Clinics Held in 2019
- Over 20% Adjusted EBITDA Margin Enabler
- Saw over 1M pets in 2019




- Growth vehicle to treat 8M pets by 2023
- First 34 Clinics Completed in 2018
- 80 New Wellness Centers Opened in 2019
- EBITDA Acceleration Achieved with Conversion Clinics

OUR PLAN: BUILD 1000 WELLNESS CLINICS BY 2023

CONVERSION CLINICS: TURNING COMMUNICTY CLINICS INTO WELLNESS CENTERS



OUR CONVERSION MODEL IS OUR COMPETITIVE ADVANTAGE




OUR LAUNCH MODEL IS PROVEN SCALABLE











AND OUR PET OWNERS HAVE TOLD US, WE DO IT VERY WELL

And Doing it Well

Customer satisfaction is very high




Best in Class Promoter Scores



Cost considerations and walk-in ability are mentioned by the majority of pet owners as reasons to visit a PetIQ location over a traditional vet.

Reasons to Visit Rig/Wellness Center



Source: VIP Customer Profiling Market Research, Market Vision Research, December, 2019.

FORECASTED PET GROWTH 2018 - 2023



PET IQ.



PRODUCTS

OUR PRODUCTS REACH PET PARENTS WHERE THEY CHOOSE TO PURCHASE



PET IQ.

STATE OF THE ART OTC MANUFACTURING & DISTRIBUTION FACILITIES

- 780,000+ Square Feet of Our Own Facilities
- Over 1,200 Items Manufactured
 - Flea & Tick
 - Health & Wellness
 - Prescription Drug
 - Treats
- EPA/FDA Licensed
- SQF Certified













1375 N. Mountain Springs Pkwy Springville, Utah 84663 sqft - 240,000



PETIQ. FLORIDA

530 Fentress Blvd Daytona Beach, Florida 32114 sqft - 142,900



PETIC: TEXAS 3601 E Plano Parkway, Suite 150 Plano, Texas 75074 **sqft - 60,000**





10077 S 134th St Omaha, Nebraska 6813 **sqft - 60,000**



RECENT ACQUISITIONS TO FUEL OUR GROWTH STRATEGY



- Closed acquisition 7-8-2019
- State of the art Animal Health Manufacturing Facility
- On track for \$3MM in cost synergies for 2020
- On track to grow +15% in 2020
- Strong Brand Portfolio: Pet Armor and Sergeants
- Margin enhancer, high margin portfolio





- Signed Definitive Agreement 1-12-2020 to acquire brands, registrations, and all rights to Capstar portfolio for the USA
- Deal subject to FTC Consent Decree: PetIQ as an acceptable buyer and not contingent on the closing of the Bayer transaction
- \$95MM purchase price, financed cash and debt within our existing credit facility
- #1 Oral OTC Flea Treatment in the USA
- Highest gross margin items in the company

CONTINUED GROWTH OF VETERINARY PRODUCTS VOLUME

SOURCES OF GROWTH






SMARTER PET HEALTH

REDEFINING VETERINARY SOLUTIONS

RETAIL MARKETPLACE



VETERINARY SERVICES • PHARMACEUTICALS • PET PRODUCTS




PETIC: Delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and services.

PET IQ.



REITERATED 2019 OUTLOOK



to net income, the most comparable GAAP measure

WE ARE PETRO.

Smarter Pet Health



APPENDIX

	TWELVE MONTHS ENDING		
\$ IN THOUSANDS	2016	2017	2018
NET INCOME	(3,395)	7,817	87
PLUS:			
TAX EXPENSE (BENEFIT)	-	3,970	(661)
DEPRECIATION	1,915	2,348	6,657
AMORTIZATION	1,067	1,052	5,210
INTEREST	3,058	1,563	8,022
EBITDA	2,645	16,750	19,315
LOSS ON DEBT EXTINGUISHMENT	1,681	-	-
LITIGATION EXPENSE	3,262	_	_
COSTS ASSOCIATED WITH BECOMING A PUBLIC COMPANY	2,180	2,710	_
MANAGEMENT FEES	864	610	-
ACQUISITION COSTS	_	1,965	3,787
SUPPLIER RECEIVABLE WRITE OFF	-	(175)	_
STOCK BASED COMPENSATION EXPENSE	-	447	3,812
PURCHASE ACCOUNTING ADJUSTMENT TO INVENTORY	_	_	2,149
NON SAME-STORE REVENUE	-	_	(3,967)
NON SAME-STORE COSTS	_	_	10,345
FAIR VALUE ADJUSTMENT OF CONTINGENT NOTE	-	_	3,280
INTEGRATION COSTS AND COSTS OF DISCONTINUED CLINICS	_	_	998
NEW WELLNESS CENTER LAUNCH EXPENSES	_	_	1,380
NON-RECURRING ROYALTY SETTLEMENT	_	_	440
ADJUSTED EBITDA	10,632	22,307	41,539